Tripep presents preliminary positive results from the first patient in the ongoing ChronVac-C® study

Tripep presents preliminary positive results from the first patient in the
ongoing  ChronVac-C® study

Tripep can today report on preliminary results from the first patient in the
lowest dose group who has now  completed the treatment against hepatitis C virus
infection in the ongoing open study with the therapeutic vaccine ChronVac-C®. So
far, the treatment has been safe. Samples taken before, during and after
treatment show that before vaccination the patient did not have a detectable
cell mediated immune response against hepatitis C virus but after completed
treatment such an immune response became detectable. These results will be
presented at a scientific conference on April 5th at the annual Royal Golden
Jubilee Conference in Chonburi, Thailand.

”We are very happy that the first patient has  now  gone through the ChronVac-C®
treatment without unexpected side effects and that we have also  received data
showing the appearance of a cell mediated immune response against the hepatitis
C virus. It is known that patients who spontaneously clear their infection
develop such an immune response. Therefore it is exciting and gratifying that
ChronVac-C® is able to give rise to an immune response in the first patient. We
now look forward to the forthcoming results from all patients in the study,
particularly from those receiving a higher dose, where  the animal studies
showed a considerably more powerful immune response”, says Tripep's CEO Jan
Nilsson.

ChronVac-C® is a therapeutic vaccine, i.e. it is given to individuals already
infected with the hepatitis C virus with the aim to clear the infection by
boosting the immune response against the virus. Tripep's ChronVac-C® vaccine is
administered with Inovio's Medpulser®DDS. Analysis of the immune response has
been performed by ImmuSystems GmbH, in Münich and a more detailed immunological
analysis will be conducted. The patient Tripep is reporting on today belongs to
the group receiving the lowest dose. Presently five patients are treated in the
study and no unexpected side effects have been observed.

The study is conducted at the Infectious Disease Clinic and the Center for
Gastroenterology at the Karolinska University Hospital and entails a total of 12
patients divided into three dose groups with increasing doses of ChronVac-C®.
Each patient receives four ChronVac-C® vaccinations one month apart. After the
last vaccination the patients are followed for another six months. The main
purpose of the study is to show that the treatment is safe, but also to test if
the treatment boosts the host immune response to hepatitis C, and its effect on
the virus replication in the liver. If the patient is completely virus-free six
months after completed treatment then the patient is considered cured.  The
total market for therapies against hepatitis C infections is estimated to be
over 2 billion dollars and is expected to grow to more than 8 billion dollars by
2015 according to Datamonitor. 


For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .